anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Coral diseases are significant drivers of global coral reef degradation, with pathogens dominated by Vibrio coralliilyticus playing a prominent role in the development of coral diseases. Coral phenotype, symbiotic microbial communities, and host transcriptional regulation have been well-established as factors involved in determining coral disease resistance, but the underlying mechanisms remain incompletely understood.
METHODS: This study employs high-throughput sequencing to analyse the symbiotic microbial and transcriptional response of the hosts in order to evaluate the disease resistance of Acropora valida and Turbinaria peltata exposed to Vibrio coralliilyticus.
RESULTS: A. valida exhibited pronounced bleaching and tissue loss within 7 h of pathogen infection, whereas T. peltata showed no signs of disease throughout the experiment. Microbial diversity analyses revealed that T. peltata had a more flexible microbial community and a higher relative abundance of potential beneficial bacteria compared to A. valida. Although Vibrio inoculation resulted in a more significant decrease in the Symbiodiniaceae density of A. valida compared to that of T. peltata, it did not lead to recombination of the coral host and Symbiodiniaceae in either coral species. RNA-seq analysis revealed that the interspecific differences in the transcriptional regulation of hosts after Vibrio inoculation. Differentially expressed genes in A. valida were mainly enriched in the pathways associated with energy supply and immune response, such as G protein-coupled receptor signaling, toll-like receptor signaling, regulation of TOR signaling, while these genes in T. peltata were mainly involved in the pathway related to immune homeostasis and ion transport, such as JAK-STAT signaling pathway and regulation of ion transport.
CONCLUSIONS: Pathogenic challenges elicit different microbial and transcriptional shifts across coral species. This study offers novel insights into molecular mechanisms of coral resistance to disease.
A novel member of the human AMPK family is identified and named ARK5 (AMPK-Related Kinase 5). In nutritional hunger, ARK5 Akt-dependently supports the survival of cells. A P/ARK cell line constructed by stably transfecting PANC-1, which is a human pancreatic cancer cell line, with ARK5 shows an in vitro metastatic activity twice or more as high as PANC-1 does. In a nude mouse, the P/ARK cell line shows more than 10-fold increase in tumor proliferation 12 weeks after transplantation. The P/ARK cell line shows a significant decrease in the necrotic area in a transplanted tumor nest compared with the parent PANC-1 cells. A nude mouse having the P/ARK cell line transplanted thereto shows obvious intramuscular infiltration and mesenteric metastasis.
The invention provides an acetazolamide composition lyophilized tablet and a preparation method thereof and relates to the technical fields of medicines and medicine production. The acetazolamide composition lyophilized tablet comprises acetazolamide, starch and cane sugar. By taking starch and cane sugar as auxiliary materials, heating process is carried out on common corn starch, so that the bonding and disintegrating effects of starch in the tablet can be improved and the formability of the tablet is improved. The acetazolamide composition lyophilized tablet just needs two auxiliary materials: starch and cane sugar. According to the acetazolamide composition lyophilized tablet, by adopting a lyophilizing process of increasing and decreasing the temperature twice, the formability of the tablet is good due to temperature increase and decrease twice, so that the dissolution rate of the tablet is improved, thereby improving the bioavailability of the tablet. The tablet is used for overcoming the defects of common acetazolamide tablet and reducing the types and use level of auxiliary materials in the acetazolamide tablet, is good in dissolution rate and high in bioavailability and can be used for ensuring the curative effect and safety of clinical medication.
The mind body intervention is delivered by podcast and material posted online. All session content will be audio recorded into 15-min audio-recordings that will be delivered on a podcast platform. During the course of the 4-week program, one new "podcast session" will be delivered every day.
Learning and memory impairment (LMI), a common degenerative central nervous system disease. Recently, more and more studies have shown that Ganoderma lucidum (GL) can improve the symptoms of LMI. The active ingredients in GL and their corresponding targets were screened through TCMSP (Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform) and BATMAN-TCM (Bioinformatics Analysis Tool for Molecular Mechanism of Traditional Chinese Medicine) databases, and the potential LMI targets were searched for through GeneCard (GeneCards Human Gene Database) and DrugBank. Then, we construct a 'main active ingredient-target' network and a protein-protein interaction (PPI) network diagram.The GO (Gene Ontology) functional enrichment analysis and KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway annotation analysis were performed on the common targets through DAVID (Database for Annotation Visualization and Integrated Discovery) to clarify the potential molecular mechanism of action of active ingredients in GL. The tumor necrosis factor (TNF) protein was verified by Western blot; Twenty one active ingredients in GL and 142 corresponding targets were screened out, including 59 targets shared with LMI. The 448 biological processes shown by the GO functional annotation results and 55 signal pathways shown by KEGG enrichment analysis were related to the improvement of LMI by GL, among which the correlation of Alzheimer's disease pathway is the highest, and TNF was the most important protein; TNF can improve LMI. GL can improve LMI mainly by 10 active ingredients in it, and they may play a role by regulating Alzheimer's disease pathway and TNF protein.
Participants randomly assigned to this group receive: 1) technology-assisted self-monitoring of daily activity via a Fitbit Zip worn daily (for 8 weeks) and a daily tablet self-report survey (completed for a 7-day period at baseline and a second 7-day period 4-weeks later). While it is expected that wearing the Fitbit and raising consciousness of activity engagement may initially result in behavior change, it is not expected to have a sustained impact on outcomes over time.
Families allocated in the intervention group will receive the whole skin roasted peanuts packed in daily doses (25 g per day, 750 g per month), starting the day that we will visit the participants for the first time. They will consume 25 g of whole skin roasted peanuts as a daily snack to be incorporated into their diet for six months.
PCT No. PCT/IB94/00114 Sec. 371 Date Jan. 17, 1996 Sec. 102(e) Date Jan. 17, 1996 PCT Filed May 19, 1994 PCT Pub. No. WO95/03033 PCT Pub. Date Feb. 2, 1995An osmotic device that, following the imbibement of water vapor, provides for the controlled release of a beneficial agent to an aqueous environment. The device comprises a hydrophilic formulation including a beneficial agent, and if needed, an osmagent, surrounded by a wall. The wall is formed at least in part of a semipermeable hydrophobic membrane having an average pore size between about 0.1  mu m and 30  mu m. The pores are substantially filled with a gas phase. The hydrophobic membrane is permeable to water in the vapor phase and the hydrophobic membrane is impermeable to an aqueous medium at a pressure less than about 100 Pa. The beneficial agent is released, for example, by osmotic pumping or osmotic bursting upon imbibement of sufficient water vapor into the device core. These devices minimize incompatibilities between the beneficial agent and ions (such as hydrogen or hydroxyl) or other dissolved or suspended materials in the aqueous medium, since contact between the beneficial agent and the aqueous medium does not occur until after the beneficial agent is released. This results from the semipermeable membrane's selective permeability for water vapor. In addition, the high water fluxes attendant with these vapor-permeable membranes facilitate the delivery of beneficial agents having low solubilities, and the delivery of high dosages of beneficial agents.
Provided are methods for labeling ultrasound data. The method may include training a convolutional neural network (CNN) based on ultrasound data. The ultrasound data may include ultrasonic waveform data (e.g., radio frequency (RF) waveform data). An RF input of each downsampling layer of a plurality of downsampling layers in the CNN may be downsampled. The RF input may include RF waveform data for an ultrasound. Tissues in the ultrasound may be segmented based on an output of the CNN. A system is also disclosed.
Pyroptosis is a recently identified type of pro-inflammatory programmed cell death (PCD) mediated by inflammasomes and nucleotide oligomerization domain-like receptors (NLs) and dependent on members of the caspase family. Pyroptosis has been widely reported to participate in the occurrence and progression of various inflammatory diseases, including stroke, a frequently lethal disease with high prevalence and many complications. To date, there have been no effectively therapeutic strategies and methods for treating stroke. Pyroptosis is thought to be closely related to the occurrence and development of stroke. Understanding inflammatory responses induced by the activation of pyroptosis would be hopeful to provide feasible approaches and strategies. Targeting on molecules in the upstream or downstream of pyroptosis pathway has shown promise in the treatment of stroke. The present review summarizes current research on the characteristics of pyroptosis, the function and pathological phenomena of pyroptosis in stroke, the molecule mechanisms related to inflammatory pathways, and the drugs and other molecules that can affect outcomes after stroke. These findings may help identify possible targets or new strategies for the diagnosis and treatment of stroke.
Participants in the Weekly Weigh-In arm will be asked to weigh in each week during a 12 week intervention period. Participants will be asked to complete a final weight measurement at week 24.
All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
In the controlled clinical trials, mild pain (including transient burning and stinging) was reported by about 30% of patients in both the active and placebo arms; treatment was discontinued in 2 of these patients. Local pruritus occurred in 4% of these patients. In all studies, there was no significant difference between the drug and placebo group in the rate or type of reported adverse reactions nor were there any differences in abnormal clinical laboratory findings. 

  


Observed During Clinical Practice: Based on clinical practice experience in patients treated with acyclovir ointment 5% in the US, spontaneously reported adverse events are uncommon. Data are insufficient to support an estimate of their incidence or to establish causation. These events may also occur as part of the underlying disease process. Voluntary reports of adverse events that have been received since market introduction include: 

General: Edema and/or pain at the application site. 

Skin: Pruritus, rash.
BACKGROUND: Anaplastic thyroid cancer (ATC) is highly invasive, prone to distant metastasis (DM), and has a very poor prognosis. This study aims to construct an accurate survival prediction model for ATC patients with DM, providing reference for comprehensive assessment and treatment planning.
METHODS: We extracted data of ATC patients with DM diagnosed between 2004 and 2019 from the SEER database, randomly dividing them into a training set and a validation set in a ratio of 7:3. Univariate and multivariate Cox regression analyses were sequentially performed on the training set to identify independent prognostic factors for overall survival (OS) and construct nomograms for 3-month, 6-month, and 8-month OS for ATC patients with DM based on all identified independent prognostic factors. Receiver operating characteristic (ROC) curve analysis, decision curve analysis (DCA) curve analysis, and calibration curves were separately plotted on the training and validation sets to demonstrate the model's performance. Furthermore, patients were stratified into high- and low-risk groups based on their risk scores, and the Kaplan-Meier (KM) survival curves were used to illustrate the survival differences between the two groups.
RESULTS: A total of 322 patients were included in this study. Univariate and multivariate Cox regression analyses identified five independent prognostic factors for OS in ATC patients with DM: surgery, tumor size, age, chemotherapy, and radiotherapy. Nomograms for 3-month, 6-month, and 8-month OS were established based on these factors. The training set AUC values (3-month AUC: 0.767, 6-month AUC: 0.789, 8-month AUC: 0.795) and validation set AUC values (3-month AUC: 0.753, 6-month AUC: 0.798, 8-month AUC: 0.806) as well as the calibration curves demonstrated excellent applicability and accuracy of the model. Additionally, the DCA curves indicated substantial clinical net benefit of the model. The KM curves also confirmed the model's excellent stratification ability for patient OS.
CONCLUSION: The nomogram developed in this study accurately predicts OS for ATC patients with DM. It can assist clinicians in formulating appropriate treatment strategies for these patients.
BACKGROUND: The rise in injection drug use in the USA has led to an increase in injection site infections. We performed a national survey of people who use drugs to evaluate common drug use preparation, harm reduction practices, and experiences with injection site infections.
METHODS: A survey was disseminated to members of the Survey of Key Informants' Patients Program from 2021 to 2022 and distributed to patients 18 years or older newly entering one of 68 substance use disorder treatment programs across the USA with a primary diagnosis of an opioid use disorder. Participants were surveyed about practices when preparing and using drugs, along with self-reported infections and drug use complications.
RESULTS: 1289 participants responded to the survey. Sexually transmitted infections were common, with 37.6% reporting ever having had any sexually transmitted infection. Injection-associated infections had affected 63.4% of participants who had ever used injection drugs. Many respondents reported not seeking professional medical assistance for infection management, including 29% draining abscesses without seeking medical care and 22.8% obtaining antibiotics through non-healthcare sources. Non-sterile injection practices included sharing needles with others who were febrile or ill (18%), using needles previously used to drain wounds/abscesses (9.9%) for subsequent injection drug use, and licking needles (21.2%).
CONCLUSION: Patients entering treatment for opioid use disorder reported a high burden of infectious diseases. A number of easily-modifiable high risk behaviors for developing injection-related infections were identified. Efforts are needed to disseminate targeted harm reduction education to PWID on how to reduce their risks for injection-related infections.
PURPOSE: Since the literature currently provides controversial data on the postoperative outcomes following right and left hemicolectomies, we carried out this study to examine the short- and long-term treatment outcomes.
METHODS: This study included consecutive patients who underwent right or left-sided colonic resections from year 2014 to 2018 and then they were followed up. The short-term outcomes such as postoperative morbidity and mortality according to Clavien-Dindo score, duration of hospital stay, and 90-day readmission rate were evaluated as well as long-term outcomes of overall survival and disease-free survival. Multivariable Cox regression analysis was performed of overall and progression-free survival.
RESULTS: In total, 1107 patients with colon tumors were included in the study, 525 patients with right-sided tumors (RCC) and 582 cases with tumors in the left part of the colon (LCC). RCC group patients were older (P < 0.001), with a higher ASA score (P < 0.001), and with more cardiovascular comorbidities (P < 0.001). No differences were observed between groups in terms of postoperative outcomes such as morbidity and mortality, except 90-day readmission which was more frequent in the RCC group. Upon histopathological analysis, the RCC group's patients had more removed lymph nodes (29 ± 14 vs 20 ± 11, P = 0.001) and more locally progressed (pT3-4) tumors (85.4% versus 73.4%, P = 0.001). Significantly greater 5-year overall survival and disease-free survival (P = 0.001) were observed for patients in the LCC group, according to univariate Kaplan-Meier analysis.
CONCLUSIONS: Patients with right-sided colon cancer were older and had more advanced disease. Short-term surgical outcomes were similar, but patients in the LCC group resulted in better long-term outcomes.
Patients receive pembrolizumab IV over 30 minutes, and within 6 hours also receive 64Cu-DOTA-pembrolizumab via slow IV push over \> 1 minute on day 0. Patients then undergo PET over 60 minutes on day 1.
To provide an emulsification composition and cosmetic composition in which an oily component is not limited to a vegetable oil and also xanthan gum and welan gum need not be essential components, and provide a method for producing the emulsification composition.SOLUTION: An emulsified composition comprises an oily component, an aqueous dispersion medium, an emulsifier, and cellulose nanofibers. Cellulose nanofibers serve as an emulsion stabilizer and are defibrated native cellulose. The amount of the emulsifier blended is less than 20% by mass of the total amount of the emulsified composition. A cosmetic composition includes the emulsified composition. A method for producing an emulsified composition includes the step of adjusting an oil phase, adjusting an aqueous phase, and carrying out emulsification by mixing the oil phase and the aqueous phase. The addition of cellulose nanofibers obtained by defibrating unmodified cellulose is carried out in at least one of an aqueous phase preparation step and an emulsification step. The addition of an emulsifier is carried out in at least one of the oil phase preparation step, the aqueous phase preparation step, and the emulsification step.SELECTED DRAWING: Figure 1
PROBLEM TO BE SOLVED: To obtain a weakened dengue virus having genetically extreme stability without reversion to high virulent, useful for producing a vaccine, etc. by subjecting a dengue virus separated from a dengue fever patient of slight disease to passage to the sensitive cell of the dengue virus. SOLUTION: A dengue virus separated from a dengue fever patient of slight disease is subjected to passage to the sensitive cell of the dengue virus to give a weakened dengue virus such as ThNHp 11/93 strain, etc. A monofunctional or polyfunctional dengue fever vaccine is prepared by making the vaccine include the weakened dengue virus as an active ingredient in an amount to perform immunity. A mixed vaccine is preferably prepared by making the vaccine include the weakened dengue virus as one of plural active ingredients in an amount to preform immunity. The dose of the vaccine is 0.2-1.0 ml per adult.
PURPOSE:To provide the title external preparation giving marked medicinal virtues along with developing no side effects, containing, as active ingredient, squalene. CONSTITUTION:The objective external preparation containing 10-50 (pref. 15-35) wt.% of squalene which has been widely used in cosmetics and soaps, etc. The dosage of the present external preparation to be applied is pref. 0.01-1g/3.14cm<2>/ day on a squalene basis. The present external preparation has pharmaceutical effect comparable to, or higher than those for conventional dermal external preparations comprising adrenocortical hormones.
No hydration for patients without chronic kidney disease(CrCl\<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
BACKGROUND: In recent years, arthroscopic lateral ankle ligament repair has become increasingly popular. However, reports on the clinical outcomes of arthroscopic ankle stabilization for skeletally immature patients remain scarce. This study investigated the clinical outcomes of arthroscopic lateral ankle ligaments repair in skeletally immature patients compared to skeletally mature patients.
METHODS: Our retrospective analysis compared skeletally immature patients and skeletally mature adults who underwent arthroscopic repair of the ankle lateral ligaments with a modified lasso-loop stitch using a suture anchor. Skeletal immaturity was defined as patients whose epiphyseal line of the distal fibula remained open on plain radiography. Clinical outcomes were evaluated using the Self-Administered Foot Evaluation Questionnaire (SAFE-Q) at 2 years after surgery. The time to postoperative walking, jogging, and return to full sports activities were also evaluated.
RESULTS: Sixty-four skeletally immature patients (IM group) and 103 skeletally mature adults (M group) were included. No significant differences were observed during both walking and jogging after surgery between the groups; however, return to full athletic activities was significantly earlier in IM group (P = .05). The mean scores in all SAFE-Q subscales significantly improved in both groups after surgery (P < .001). There were also no statistically significant differences between the groups in the mean postoperative SAFE-Q scores for all subscales. All patients in the IM group returned to playing sports at their preinjury levels postoperatively.
CONCLUSION: We found that skeletally immature patients with chronic lateral ankle instability had generally similar responses to arthroscopic lateral ankle as skeletally mature adult patients at minimally 2 years' follow-up with a high rate of successful return to sport.
LEVEL OF EVIDENCE: Level III, retrospective case control study.
In group-2, hematoma with a greater thickness was removed first (if thickness was equal on both sides, first incision was made on the right side). The head in supine position was rotated to the side with a smaller hemorrhage thickness. Previously, burr holes were made, the dural surfaces were exposed, the outer membrane opened, and the hematoma was evacuated at one side. Then, drainage system inserted into the subdural space. After the procedure of the first side was completed, as a consecutive process, the head was rotated to the other side, and the same procedure was repeated.
Participants ages 12 to \<18 years old will receive cobicistat 150 mg with either ATV or DRV plus background regimen (BR). The BR may contain additional antiretroviral agents except for the following disallowed agents: saquinavir, indinavir, nelfinavir, double protease inhibitor (PI) regimens, raltegravir, elvitegravir, efavirenz, nevirapine, delavirdine, maraviroc, etravirine, rilpivirine, dolutegravir, and investigational antiretroviral agents.
PECS II; The block will be performed in the supine position of the patient, just anterior to the axillary line at the level of the 4th rib. After visualizing the serratus anterior, pectoralis major, and pectoralis minor muscles along with the ribs and pleura, the needle will be directed in-plane from cranial to caudal into the fascia of the serratus anterior muscle. Subsequently, 30 ml of bupivacaine with a 0.25% concentration will be applied.